Abnova公司來自中國臺灣，是目前世界上zui大的單克隆抗體和蛋白生產(chǎn)商之一，現(xiàn)有抗體數(shù)量近4萬種，蛋白超過16000種，并具有每月研發(fā)500種小鼠單克隆抗體和500種兔源多克隆抗體的技術(shù)和實力。與傳統(tǒng)抗體生產(chǎn)技術(shù)不同，Abnova使用其*的基因組和蛋白質(zhì)組的方法來制備和生產(chǎn)抗體，其目標(biāo)是為人類基因組內(nèi)表達(dá)的每一個基因都提供至少一種抗體。Abnova生產(chǎn)的所有產(chǎn)品，重組蛋白和抗體均采用目前上的生產(chǎn)和SPF級動物設(shè)施。和傳統(tǒng)的單克隆抗體生產(chǎn)方法相比，Abnova采用更*的蛋白生產(chǎn)技術(shù)和設(shè)備，可以極大地提高單克隆抗體的生產(chǎn)效率并降低其生產(chǎn)的成本。其的小麥胚芽體外蛋白表達(dá)系統(tǒng)（Wheat Germ In Vitro Protein Expression System），利用小麥胚芽萃取物可高效率執(zhí)行體外mRNA翻譯蛋白質(zhì)的特點，快速生產(chǎn)高品質(zhì)和功能高度相似的蛋白質(zhì)，能更有效的用于生產(chǎn)抗體尤其適合于制備功能蛋白并用于生產(chǎn)抗體。MaxPab□技術(shù)是Abnova的抗體生產(chǎn)技術(shù)，其生產(chǎn)的抗體能雙重識別蛋白一級結(jié)構(gòu)及三級結(jié)構(gòu)的抗原表位，非常適合用于免疫學(xué)檢測，具有高反應(yīng)性、高靈敏性和高特異性的特點。Abnova對所生產(chǎn)的產(chǎn)品提供的質(zhì)量保證（說明書驗證的實驗方法和種屬），讓您無憂無慮使用抗體：
Abnova是世界上zui大的單克隆抗體生產(chǎn)商之一，現(xiàn)有抗體產(chǎn)品種類近30000種，其中2/3是單克隆抗體。和傳統(tǒng)的單克隆抗體生產(chǎn)方法相比，Abnova采用更*的技術(shù)和設(shè)備，可以極大地提高單克隆抗體的生產(chǎn)效率并降低其生產(chǎn)的成本。Abnova具有每個月開發(fā)500個小鼠單克隆抗體的能力，他們的目標(biāo)是：人類基因組中的每一個表達(dá)基因都至少有一種抗體。

The Gap between Genomics and Proteomics

After the completion of human genomic project, most human expressed genes have been identified, and full-length cDNA of these genes have become publicly available. In the emerging proteomics era, proteins act as the key players in the unveiling of these genes. In order to effectively decipher the mystery of these proteins, antibodies with their inherent sensitivity and specificity thus become the most versatile tools for providing one-to-one relationship with their target proteins. 

What Abnova Does

The mission of Abnova is to become a leader in high throughput antibody and protein production. Abnova intends to become worlds largest protein and antibody catalog company by building a full collection of essential proteins and their antibodies targeting the human genome.  

Why Choose Abnova?

Abnova offers a unique complete monoclonal antibody and protein experience for our customer that is different from traditional custom production companies and laboratories.

Industrial-Scale Infrastructure: We maintain a streamlined monoclonal production facility with scalable capacity for up to 500 immunization per month, and a state-of-the-art specific pathogen free （SPF） facility, which has the breeding and holding capacity for 10,000+ mice. These facilities allow us to significantly bring down the cost of customized monoclonal antibody production. We have also incorporated numerous automation systems into our production line, which significantly increased our efficiency.

Wheat Germ In Vitro Protein Expression System: We have a high throughput protein production system, which allows soluble expression of conformational correct protein either from full-length cDNA or specific domains.